Targeted therapeutic options and future perspectives for HER2-positive breast cancer

Abstract

Over the past 2 decades, there has been an extraordinary progress in the regimens developed for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer. Trastuzumab, pertuzumab, lapatinib, and ado-trastuzumab emtansine (T-DM1) are commonly recommended anti-HER2 target agents by the U.S. Food and Drug Administration. This review summarizes the most significant and updated research on clinical scenarios related to HER2-positive breast cancer management in order to revise the guidelines of everyday clinical practices. In this article, we present the data on anti-HER2 clinical research of neoadjuvant, adjuvant, and metastatic studies from the past 2 decades. We also highlight some of the promising strategies that should be critically considered. Lastly, this review lists some of the ongoing clinical trials, findings of which may soon be available.

Cited by papers we hold 12

• Biomarkers as Biomedical Bioindicators: Approaches and Techniques for the Detection, Analysis, and Validation of Novel Biomarkers of Diseases · 2023
  No notice
• Cardiotoxicity of Anticancer Drugs: Molecular Mechanisms and Strategies for Cardioprotection · 2022
  No notice
• Breast Cancer Metastasis: Mechanisms and Therapeutic Implications · 2022
  No notice
• Modular cytokine receptor-targeting chimeras for targeted degradation of cell surface and extracellular proteins · 2022
  No notice
• Targeting mutations in cancer · 2022
  No notice
• Combining losartan with radiotherapy increases tumor control and inhibits lung metastases from a HER2/neu-positive orthotopic breast cancer model · 2021
  Not checked
• Breast Cancer Treatments: Updates and New Challenges · 2021
  No notice
• Spatial deconvolution of HER2-positive breast cancer delineates tumor-associated cell type interactions · 2021
  No notice
• Current State of Breast Cancer Diagnosis, Treatment, and Theranostics · 2021
  No notice
• Liposomes and Extracellular Vesicles as Drug Delivery Systems: A Comparison of Composition, Pharmacokinetics, and Functionalization · 2021
  No notice
• Cancer Stem Cells—Origins and Biomarkers: Perspectives for Targeted Personalized Therapies · 2020
  No notice
• Breast Cancer: A Molecularly Heterogenous Disease Needing Subtype-Specific Treatments · 2020
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.